Structure activity studies on pseudo-symmetrical HIV-1 protease inhibitors
A series of pseudo-symmetrical HIV-1 protease inhibitors was synthesized and evaluated for their ability to act as anti-viral agents. Compound 17 was found to be the most potent enzyme inhibitor and anti-viral agent of those prepared.
References (12)
- et al.
Bioorg. Med. Chem. Lett.
(1992) - et al.
J. Am. Chem. Soc.
(1982) VIIth International Conference on AIDS
(1992)- et al.
J. Org. Chem.
(1992)et al.Bioorg. Med. Chem. Lett.
(1992)et al.J. Med. Chem.
(1992) - et al.
203rd ACS National Meeting
(April 1992)
There are more references available in the full text version of this article.
Cited by (9)
Synthesis of dibenzyl iminodiacetic derivatives as potential inhibitors of HIV-1 aspartyl protease
1998, European Journal of Medicinal ChemistryPeptoid mimics of a C<inf>2</inf>-symmetric inhibitor of the HIV-1 protease.
1994, Bioorganic and Medicinal Chemistry LettersSynthesis of C<inf>2</inf>-symmetric inhibitors of the HIV-1 protease, with N,N′-substituted ethylenediamide and ethylenediamine linkers.
1994, Bioorganic and Medicinal Chemistry LettersDesign, structure activity and x-ray crystallographic studies of pseudosymmetrical nonpeptidyl HIV-1 protease inhibitors
1994, Bioorganic and Medicinal Chemistry LettersAsymmetric synthesis of cis- and trans-γ-lactones useful in HIV-1 protease inhibitor synthesis
1994, Bioorganic and Medicinal Chemistry LettersProtease inhibitors for the treatment of HIV/AIDS: Recent advances and future challenges
2019, Current Topics in Medicinal Chemistry
- 1
Present address: Agouron Pharmaceuticals Inc. 3565 General Atomics Ct. San Diego, CA 92121
- 2
Department of Medicine, Hematology/Oncology Research Laboratory, New England Deaconess Hospital, Boston, MA 02215
Copyright © 1993 Published by Elsevier Ltd.